The BCMA-directed bispecific antibody will now be available for use on the NHS in England via the Cancer Drugs Fund (CDF) while more evidence is collected about its effectiveness.
Patients eligible for the drug will have received at least three lines of treatment, including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody, and will have experienced disease progression on the last therapy…
